Mutational spectrum of myeloid malignancies with inv(3)/t(3;3) reveals a predominant involvement of RAS/RTK signaling pathways.
about
Molecular landscape of acute myeloid leukemia in younger adults and its clinical relevanceGenomic Classification and Prognosis in Acute Myeloid Leukemia.Epigenetic Guardian: A Review of the DNA Methyltransferase DNMT3A in Acute Myeloid Leukaemia and Clonal Haematopoiesis.Regulatory landscape fusion in rhabdomyosarcoma through interactions between the PAX3 promoter and FOXO1 regulatory elementsComprehensive mutational profiling of core binding factor acute myeloid leukemia.Clinical and prognostic significance of 3q26.2 and other chromosome 3 abnormalities in CML in the era of tyrosine kinase inhibitors.Distinct evolution and dynamics of epigenetic and genetic heterogeneity in acute myeloid leukemia.Mutational Landscape and Gene Expression Patterns in Adult Acute Myeloid Leukemias with Monosomy 7 as a Sole Abnormality.Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel.Buparlisib, a PI3K inhibitor, demonstrates acceptable tolerability and preliminary activity in a phase I trial of patients with advanced leukemias.3q26/EVI1 rearrangements in myeloid hemopathies: a cytogenetic review.Review: Aberrant EVI1 expression in acute myeloid leukaemia.The mutational oncoprint of recurrent cytogenetic abnormalities in adult patients with de novo acute myeloid leukemia.Splicing factor mutations in MDS RARS and MDS/MPN-RS-T.Genetic and epigenetic heterogeneity and the impact on cancer relapse.Predictive value of high EVI1 expression in AML patients undergoing myeloablative allogeneic hematopoietic stem cell transplantation in first CR.Acute myeloid leukemia with 3q26 abnormality: An editorial perspective.
P2860
Q26776393-F9BD2309-671C-4586-8D53-4AB00F3890E0Q27853389-EB92C930-ADEB-45BA-8BD9-42BAEBB97028Q30235316-CBDB7EC6-263A-49C0-AB34-4DF1A7E2C059Q30855713-FE36CA34-A818-49BB-A93B-2E803BE8627EQ33758306-48368429-5DEB-4AB4-99A6-18B61061C7AFQ36219652-57EACA1E-80CA-49C7-9ACE-CD62F169A5C5Q37079676-6E578A25-233F-4BD0-90DF-6711BA665494Q37560138-42A93287-B6A8-4C22-A2DA-739470E78BB6Q37624593-8296B2EE-D243-463D-9BB7-FDE5873200C1Q37715074-127BAE74-467E-43D6-8912-4D4AAA31C28DQ38515835-EFF10CF8-15C0-41E1-AA8F-84EA23FC2E26Q38686515-65977339-DB94-40CA-8FCE-54380DB179F6Q38892311-FE12A72F-6655-4B1C-8A81-F2E17264A3B5Q39279998-68C6183B-828A-4EE8-A89F-ADF8B1143C9DQ39433546-39DB17D9-DC76-416F-8CCF-A97AC3278367Q53162006-4DE38992-DAAF-478F-BD9A-01514DF5D6ACQ54966886-9EA1EDE3-51B3-4199-95B5-00AA0CC7FBC4
P2860
Mutational spectrum of myeloid malignancies with inv(3)/t(3;3) reveals a predominant involvement of RAS/RTK signaling pathways.
description
2014 nî lūn-bûn
@nan
2014 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Mutational spectrum of myeloid ...... of RAS/RTK signaling pathways.
@ast
Mutational spectrum of myeloid ...... of RAS/RTK signaling pathways.
@en
type
label
Mutational spectrum of myeloid ...... of RAS/RTK signaling pathways.
@ast
Mutational spectrum of myeloid ...... of RAS/RTK signaling pathways.
@en
prefLabel
Mutational spectrum of myeloid ...... of RAS/RTK signaling pathways.
@ast
Mutational spectrum of myeloid ...... of RAS/RTK signaling pathways.
@en
P2093
P2860
P50
P1433
P1476
Mutational spectrum of myeloid ...... of RAS/RTK signaling pathways.
@en
P2093
Annelieke Zeilemaker
Claudia Erpelinck
Eric M J Bindels
H Berna Beverloo
Marije Havermans
Mathijs A Sanders
Peter J M Valk
Remco Hoogenboezem
Ruud Delwel
Stefan Gröschel
P2860
P304
P356
10.1182/BLOOD-2014-07-591461
P407
P577
2014-11-07T00:00:00Z